Chonluten for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Chonluten for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Chonluten is a three-amino-acid peptide sold as the lung member of a family of organ-targeted compounds developed in Russian laboratories. Nothing has been measured in a living person, and the airway claim driving its marketing rests on a different, related peptide. With no approval, safety record or oversight, the hazard is the product itself. (Full Review)

Protocol

Synthetic tripeptide course
1–2 mg daily for 10–20 days
Subcutaneous convention, not trial evidence, from a 20 mg freeze-dried vial. Oral synthetic versions roughly 200 µg daily for 30 days.
Oral capsule complex course
1–2 capsules of roughly 10 mg
Cattle-lung extract, conventionally once or twice daily with food, 10–30 consecutive days, two to three times a year.
Best time of day
Morning, single daily dose
No dose-timing data exist; convention places the dose in the morning. Oral forms are taken with food.
Time to effect
Subjective change
Undefined; convention expects 10–30 days
No trial has measured onset for any endpoint; without controlled comparison, indistinguishable from placebo response.

Benefits

Contraindications
  • Active malignancy, or cancer treated within 5 years
  • Immune checkpoint inhibitors, during and 6 months after
  • Solid-organ transplant on maintenance immunosuppression
  • Active untreated infection, including active tuberculosis
  • Autoimmune disease on active biologic therapy
  • Pregnancy and lactation
  • Age under 18
  • Bovine-material hypersensitivity (capsule preparation)
  • Severe hepatic impairment (Child-Pugh C) or kidney filtration below 30 mL/min/1.73 m²
Key Interactions
  • Systemic corticosteroids (prednisone, dexamethasone, budesonide)
  • TNF-α inhibitors (adalimumab, etanercept, infliximab)
  • Non-steroidal anti-inflammatories (ibuprofen, naproxen, aspirin)
  • N-acetylcysteine
  • Anti-inflammatory supplements (curcumin, omega-3, boswellia, quercetin)
  • Other peptide bioregulators (Bronchogen, Thymalin, Vilon)
  • Other immune modulators (low-dose naltrexone, sirolimus)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Contaminated, Mislabeled or Underdosed Product
    •
  • Speculative: Blunted Innate Immune Response; Proliferative Signaling in Transformed Cells; Programmed Cell Death Shift in Monocytes; Injection-Site and Hypersensitivity Reactions; Transmissible Agents in Animal-Derived Preparations

Monitoring

Marker Target Why
High-sensitivity C-reactive protein Below 0.5 mg/L Primary systemic inflammation readout
Interleukin-6 Below 1.5 pg/mL Tests the cytokine suppressed in cell studies
Full blood count with differential Neutrophil-to-lymphocyte ratio 1.0–2.0 Detects blunted immune reserve
Absolute eosinophil count Below 300 cells/µL Marks allergic airway inflammation
Spirometry (FEV1/FVC) Ratio above 0.80, FEV1 above 90% predicted Only objective measure of the claimed outcome
Fractional exhaled nitric oxide Below 20 ppb Non-invasive airway inflammation marker
Resting oxygen saturation 96–99% Cheap daily gauge of gas exchange
Salivary secretory immunoglobulin A Track change from own baseline Mucosal immune defense
Comprehensive metabolic panel Within laboratory reference range Baseline organ safety; no toxicology data

Cadence: Baseline before a first course, again at its end, again 8 weeks after stopping, then every 6–12 months if courses continue.

Qualitative Assessment

  • Cough frequency and sputum volume, recorded daily
  • Breathlessness on a fixed exertion task
  • Number and duration of respiratory infections per season
  • Nocturnal waking attributable to cough
  • Daytime energy and exercise tolerance
  • Any injection-site reaction, rash or fever
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.